Axxiem Web Solutions Forms Clinical Advisory Board for AxxiTRIALS Clinical Trial Community Portal

Share Article

Experienced Clinical Trial Experts to Provide Strategic Product Direction

“The addition of these highly experienced individuals to the AxxiTRIALS advisory team will provide us with expert feedback on our product design and functionality."

Axxiem is pleased to announce the formation of its Clinical Advisory Board to provide strategic input and direction for the AxxiTRIALS Clinical Trial Community Portal. In addition to internal Axxiem staff members, Axxiem has recruited clinical trial experts to assist us as we continue to develop and enhance the AxxiTRIALS product line. “The addition of these highly experienced individuals to the AxxiTRIALS advisory team will provide us with expert feedback on our product design and functionality, in addition to business savvy based upon their individual achievements in start-up environments,” added Susan M.H. Lewenz, President and CEO of Axxiem. These experts are:

LAURIE HALLORAN, BSN, MS, President and Chief Executive Officer
Halloran Consulting Group

Laurie founded Halloran Consulting Group ( in 1998. With over 25 years of experience in clinical affairs management with contract research organizations and biotechnology companies, Laurie is recognized as an industry expert in improving the organizational effectiveness of clinical research programs with a specialty in gap analysis and strategic planning. Prior to founding Halloran Consulting Group, Laurie spent 10 years at PAREXEL International where she developed worldwide training capabilities with the clinical operations group. She has also established clinical operations at OXiGENE and Antigenics.

ALAN BOYD, R.PH., Chief Executive Officer
CNS Vital Signs, Inc.

Alan has been employed in a variety of roles in the pharmaceutical industry over the past 20 years. He has served as a consultant across many facets of the pharmaceutical and CRO industries ranging from marketing to drug development. He has also been a principle member of, as well as an advisor to, several start-up companies and angel funds. Presently, Alan is CEO of CNS Vital Signs (, which offers a technical platform utilized to clinically assess neurocognitive pathology and cognitive drug effects.

ANNE V. SHEMER, PH.D., President
Anne Shemer Consulting

Dr. Anne Shemer is a pharmaceutical executive with over 25 years of experience in clinical development and marketing. Her focus includes international clinical trials design and supervision, site selection and training, regulatory interactions, and product launch preparedness. Her clients have included companies such as Merck, Boehringer Ingelheim, Sanofi-Aventis, and Pfizer. She is multi-lingual (French, Spanish, Italian, German, and Hebrew) with a proven track record in US and EU regulatory approvals and new product launches, with specific expertise in multiple therapeutic areas such as psychotropics, stroke, pain, respiratory, gastrointestinal, infectious diseases, and neurodegenerative diseases.

KATE M. DIDIO, MBA, President
KMD Consulting, LLC

Kate Didio has 20 years of pharmaceutical, biotech and CRO experience, including over 8 years as a Director/Senior Director of Clinical Operations in small to mid-sized pharmaceutical and biotechnology companies, including Surface Logix, Inc. and Sepracor, Inc. (now Sunovion). She is currently the Senior Director of Clinical & Regulatory Affairs at Sirtris Pharmaceuticals in Cambridge, MA. Her areas of responsibility have included clinical operations, project management, regulatory operations, clinical quality assurance & risk management, pharmacovigilance, medical writing, outsourcing and data management.

Senior Director, Global Clinical Operations
Shire Human Genetic Therapies

Nancy Wyant is the Senior Director of Global Clinical Operations at Shire Human Genetic Therapies (HGT). She provides professional expertise and strong leadership in strategic program development and operational execution of clinical trials. Nancy has over 18 years of experience in the clinical research industry. Prior to her current position, she served as Director of Clinical Compliance after having started the compliance group at Shire HGT. Besides her work at Shire, Nancy has worked within clinical operations groups at Therion Biologics Corporation and Vertex Pharmaceuticals, as well as at several biopharmaceutical start-up environments.

For additional information regarding the biographies of the Advisory Board members, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dave Rosa
Visit website